BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 35354404)

  • 1. Early postoperative outcomes of staging laparoscopy for peritoneal metastases with or without pressurized intra-peritoneal aerosol chemotherapy (PIPAC).
    Teixeira Farinha H; Mattille D; Mantziari S; Demartines N; Hübner M
    BMC Surg; 2022 Mar; 22(1):122. PubMed ID: 35354404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pressurized Intraperitoneal Aerosol Chemotherapy (Oxaliplatin) for Unresectable Colorectal Peritoneal Metastases: A Multicenter, Single-Arm, Phase II Trial (CRC-PIPAC).
    Rovers KP; Wassenaar ECE; Lurvink RJ; Creemers GM; Burger JWA; Los M; Huysentruyt CJR; van Lijnschoten G; Nederend J; Lahaye MJ; Deenen MJ; Wiezer MJ; Nienhuijs SW; Boerma D; de Hingh IHJT
    Ann Surg Oncol; 2021 Sep; 28(9):5311-5326. PubMed ID: 33544279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis.
    Robella M; Vaira M; De Simone M
    World J Surg Oncol; 2016 Apr; 14():128. PubMed ID: 27125996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis.
    Demtröder C; Solass W; Zieren J; Strumberg D; Giger-Pabst U; Reymond MA
    Colorectal Dis; 2016 Apr; 18(4):364-71. PubMed ID: 26400556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIPAC-OX: A Phase I Study of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy in Patients with Peritoneal Metastases.
    Kim G; Tan HL; Sundar R; Lieske B; Chee CE; Ho J; Shabbir A; Babak MV; Ang WH; Goh BC; Yong WP; Wang L; So JBY
    Clin Cancer Res; 2021 Apr; 27(7):1875-1881. PubMed ID: 33148667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxaliplatin use in pressurized intraperitoneal aerosol chemotherapy (PIPAC) is safe and effective: A multicenter study.
    Sgarbura O; Hübner M; Alyami M; Eveno C; Gagnière J; Pache B; Pocard M; Bakrin N; Quénet F
    Eur J Surg Oncol; 2019 Dec; 45(12):2386-2391. PubMed ID: 31092362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with peritoneal surface malignancies (PSM): a prospective single-center registry study.
    Jansen-Winkeln B; Eberth J; Moulla Y; Mehdorn M; Niebisch S; Schierle K; Bläker H; Lordick F; Gockel I; Thieme R
    J Cancer Res Clin Oncol; 2023 Mar; 149(3):1331-1341. PubMed ID: 36513815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of life of patients with end-stage peritoneal metastasis treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC).
    Odendahl K; Solass W; Demtröder C; Giger-Pabst U; Zieren J; Tempfer C; Reymond MA
    Eur J Surg Oncol; 2015 Oct; 41(10):1379-85. PubMed ID: 26138283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of postoperative pain after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the treatment of peritoneal metastasis.
    Tidadini F; Abba J; Quesada JL; Villeneuve L; Foote A; Baudrant M; Bonne A; Glehen O; Trilling B; Faucheron JL; Arvieux C
    Int J Colorectal Dis; 2022 Jul; 37(7):1709-1717. PubMed ID: 35639123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility and Safety of Laparoscopic D2 Gastrectomy in Combination with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients with Gastric Cancer at High Risk of Recurrence-The PIPAC-OPC4 Study.
    Graversen M; Rouvelas I; Ainsworth AP; Bjarnesen AP; Detlefsen S; Ellebaek SB; Fristrup CW; Liljefors MG; Lundell L; Nilsson M; Pfeiffer P; Tarpgaard LS; Tsekrekos A; Mortensen MB
    Ann Surg Oncol; 2023 Jul; 30(7):4433-4441. PubMed ID: 36867174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): A bidirectional approach for gastric cancer peritoneal metastasis.
    Di Giorgio A; Schena CA; El Halabieh MA; Abatini C; Vita E; Strippoli A; Inzani F; Rodolfino E; Romanò B; Pacelli F; Rotolo S
    Surg Oncol; 2020 Sep; 34():270-275. PubMed ID: 32891341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First Clinical Safety and Feasibility Data of Whole-body Hyperthermia Pressurized Intraperitoneal Aerosol Chemotherapy (WBH-PIPAC) for Peritoneal Surface Malignancies.
    Kockelmann F; Giger-Pabst U; Ouaissi M; Bucur P; Barbey S; VON Ardenne A; Zieren J
    Anticancer Res; 2024 Jul; 44(7):3043-3050. PubMed ID: 38925817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial experience of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a French hyperthermic intraperitoneal chemotherapy (HIPEC) expert center.
    Ceribelli C; Debs T; Chevallier A; Piche MA; Bereder JM
    Surg Endosc; 2020 Jun; 34(6):2803-2806. PubMed ID: 32166545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pressurized Intraperitoneal Aerosol Chemotherapy-Related Clinical Trials in the Treatment of Peritoneal Metastases.
    Ukegjini K; Putora PM; Guidi M; Süveg K; Cihoric N; Widmann B; Steffen T
    Oncology; 2021; 99(9):601-610. PubMed ID: 34265774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncological Outcomes After Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in the Treatment of Peritoneal Carcinomatosis.
    Tidadini F; Abba J; Quesada JL; Trilling B; Bonne A; Foote A; Faucheron JL; Arvieux C
    J Gastrointest Cancer; 2023 Jun; 54(2):632-641. PubMed ID: 35778645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility and Safety of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy With or Without Intraoperative Intravenous 5-Fluorouracil and Leucovorin for Colorectal Peritoneal Metastases: A Multicenter Comparative Cohort Study.
    Taibi A; Sgarbura O; Hübner M; Bardet SM; Alyami M; Bakrin N; Durand Fontanier S; Eveno C; Gagniere J; Pache B; Pocard M; Quenet F; Teixeira Farinha H; Thibaudeau E; Dumont F; Glehen O
    Ann Surg Oncol; 2022 Aug; 29(8):5243-5251. PubMed ID: 35318519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with gastric cancer and peritoneal metastasis.
    Javanbakht M; Mashayekhi A; Branagan-Harris M; Horvath P; Königsrainer A; Reymond MA; Yaghoubi M
    Eur J Surg Oncol; 2022 Jan; 48(1):188-196. PubMed ID: 34479745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for rare gynecologic indications: peritoneal metastases from breast and endometrial cancer.
    Rezniczek GA; Giger-Pabst U; Thaher O; Tempfer CB
    BMC Cancer; 2020 Nov; 20(1):1122. PubMed ID: 33213407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RE: Phase I dose escalation study of oxaliplatin delivered via a laparoscopic approach using pressurized intraperitoneal aerosol chemotherapy (PIPAC) for advanced peritoneal metastases of gastrointestinal tract cancers: PIPAC-oxaliplatin for peritoneal metastases of gastrointestinal cancers.
    Rovers KP; Lurvink RJ; Deenen MJ; de Hingh IHJT
    Eur J Cancer; 2021 Apr; 147():182-184. PubMed ID: 33640212
    [No Abstract]   [Full Text] [Related]  

  • 20. [Perioperative safety of intraperitoneal aerosol chemotherapy : Analysis of our first 111 pressurized intraperitoneal aerosol chemotherapy (PIPAC) procedures].
    Jansen-Winkeln B; Thieme R; Haase L; Niebisch S; Pommer C; Lyros O; Zimmer J; Lordick F; Remane Y; Frontini R; Gockel I
    Chirurg; 2019 Feb; 90(2):137-145. PubMed ID: 29947920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.